Neuland Laboratories approved ₹126 crore in capital expenditure on September 7, 2026, to acquire approximately 134 acres of land in Kakinada, Andhra Pradesh. The board authorized the purchase at Auro Industrial City to support the company’s future expansion plans.

The expenditure will be financed entirely through internal accruals. The company also secured a right of first refusal to purchase an additional contiguous parcel of approximately 66 acres. This option would bring the potential aggregate land holding at the site to approximately 200 acres.

Investment Details

The board meeting held on September 7, 2026, formalized the capital allocation. The transaction falls under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

What the Numbers Show

The decision to fund a ₹126 crore land acquisition solely through internal accruals signals strong cash generation capacity. By avoiding external debt for this strategic asset purchase, the company preserves its balance sheet flexibility for future operational expenditures or capacity additions.

Malabar India Fund Limited has disposed of a significant portion of its stake in Neuland Laboratories , selling 2,72,634 equity shares through open market transactions. The sales were executed between August 10, 2024 and August 14, 2026, resulting in a reduction of the fund’s voting power from 7.18% to 5.06% of the company’s total share capital.

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Malabar India Fund Limited is not part of the promoter group of Neuland Laboratories.

Transaction Details

Neuland Laboratories’ total equity share capital remains unchanged at Rs 12,82,98,890, comprising 1,28,29,889 equity shares of Rs 10 each. There were no pledges, liens, or non-disposal undertakings associated with the shares held by Malabar India Fund Limited before or after the transaction.

What the Numbers Show

The sale represents a strategic exit of approximately 29.7% of Malabar India Fund Limited’s original holding in Neuland Laboratories. With the post-transaction stake falling below the 5% threshold often monitored for substantial acquisition disclosures, the fund’s influence on the company’s voting dynamics has diminished significantly. The absence of any convertible securities or warrants in the transaction indicates a straightforward equity liquidation rather than a restructuring of financial instruments.